Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Imetelstat Study Blip Beats Geron’s Shares Down

Executive Summary

Shares in Geron dropped by nearly 20% to $2.30 on NASDAQ on Sept. 12 following interim clinical data for its lead product, the anticancer imetelstat, from trials conducted by its partner Janssen.

Advertisement

Related Content

Imetelstat Trial Update Lift Geron, Despite Indecision By Partner J&J
Misery In Myelofibrosis: Pacritinib Setback A Boost For Jakafi
Gilead's Late-Stage R&D Misfire Gives Respite To Competing Myelofibrosis Therapies
Stockwatch: Pandora’s Interim Analysis
FDA slaps hold on imetelstat studies; Geron whipped
Geron soars on Mayo Clinic results for imetelstat

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097286

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel